We will research, develop and make available, commercially effective and affordable plant-based cannabinoid medicines specifically for treating patients suffering from cancer-related pain in the UK
First-ever Real World Evidence Study in cancer-related pain, endorsed by the National Cancer Research Institute and led by a leading clinical board across UK Cancer Hospitals.
In this introduction, we have Graeme Mc Farlane the chief commercial officer here at CBD Science. Graeme has 30+ years in the pharmaceutical industry holding senior management positions in Astra Zeneca, GlaxoSmithKline and Bristol Myers before starting two B2B companies specializing in Pharma Market Access, having brought in excess of 60 products to market in key areas of mental, cancer, and other national agenda diseases.
Interested to learn more?
1)First mover to leverage Real-World Evidence to provide accelerated access to Cannabis-based medicines in UK / Europe.
2)Accelerated access: The CBD Science Group are experts at conducting Real-World Evidence (RWE) studies that provide immediate patient enrollment in hospital settings
3)The catalyst is a collaboration between academic research institutions, hospital centres and reimbursement networks
4)Model is asset-light/risk mitigated, portable and can scale quickly while building IP
5)CBD Science Group drives data collection & develops revenue-generating cannabis-based medicine. Institutions get published opening up more access to funding, patients get solutions faster.
Learn more: https://www.cbdsciencegroup.com/
Subscribe for corporate news & investing opportunities.